MedTrace Logo

New Approaches to Cocaine Abuse Medications (A) - 6

NCT00000271 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2017-07-05

No results posted yet for this study

Summary

The purpose of this study is to measure the effect of desipramine in cocaine abusers selected for major depression or dysthymia.

Conditions

  • Cocaine-Related Disorders
  • Substance-Related Disorders

Interventions

DRUG

Desipramine

Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.

DRUG

Placebo

Participants were treated with matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • New York State Psychiatric Institute

    lead OTHER

Principal Investigators

  • Herbert Kleber, M.D. · New York State Psychiatric Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-01-31
Primary Completion
2002-10-31
Completion
2002-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000271 on ClinicalTrials.gov